Pharma C Investments - Delay in Publication of Results
30/06/2023 16:57
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd6228Ea&default-theme=true
RNS Number : 6228E Pharma C Investments PLC 30 June 2023
30 June 2023
Pharma C Investments PLC
("Pharma C" or the "Company")
Delay in Publication of Results
Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder
in the medical cannabis industry with a particular focus on companies that
provide ancillary products and services to the medicinal cannabis sectors,
announces that it will not be able to publish its audited financial statements
for the year ended 31 December 2022 by 30 June 2023, as required by the AQSE
Growth Market Access Rulebook.
The Directors currently envisage that they will be in a position to publish
the Company's results in early July and further announcements will be made in
due course.
This announcement contains inside information for the purposes of Article 7 of
the Regulation (EU) No 596/2014 on market abuse
The Directors of the Company accept responsibility for the contents of this
announcement.
For further information please visit www.pharmacinvestments.com
(http://www.pharmacinvestments.com/)
For additional information please contact:
Pharma C Investments
Gavin Sathianathan, Investment Strategy Director
gavin@pharmacinvestments.com
Novum Securities
(AQSE Corporate Adviser)
Tel: +44 207 399 9400
David Coffman
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXURVVROBUNOAR